Raphael Pharmaceutical (RAPH) EPS (Basic) (2020 - 2024)

Raphael Pharmaceutical has disclosed EPS (Basic) across 5 years of filings, most recently posting $0.02 for Q4 2024.

• EPS (Basic) for Q4 2024 came in at $0.02, up 200.0% year-over-year; the trailing twelve-month figure through Sep 2025 was $0.02 (down 33.33% YoY), and the FY2025 annual result was $0.07, down 12.5% from the prior year.
• EPS (Basic) came in at $0.02 for Q4 2024 at Raphael Pharmaceutical, up from $0.01 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.1 in Q3 2022 to a low of -$0.02 in Q4 2023.
• The 5-year median for EPS (Basic) is $0.02 (2020), against an average of $0.03.
• Across the five-year window, EPS (Basic) soared 233.33% in 2022 and slumped 128.57% in 2023, its largest moves.
• Raphael Pharmaceutical's EPS (Basic) stood at $0.02 in 2020, then surged by 200.0% to $0.06 in 2021, then rose by 16.67% to $0.07 in 2022, then plunged by 128.57% to -$0.02 in 2023, then jumped by 200.0% to $0.02 in 2024.
• The last three EPS (Basic) figures came in at $0.02 (Q4 2024), $0.01 (Q3 2024), and $0.01 (Q2 2024), per Business Quant data.